BioXcel Therapeutics, Inc. - Common Stock (BTAI)
2.9567
+0.2567 (9.51%)
Bioxcel Therapeutics is a biopharmaceutical company focused on innovative drug development to address unmet medical needs in the fields of neurology and psychiatry
Utilizing its proprietary artificial intelligence platform, the company aims to identify and advance novel therapeutics that can improve patient outcomes in challenging conditions such as agitation in Alzheimer's patients and cancer-related symptoms. Bioxcel's approach integrates data-driven decision-making and clinical research to bring forth potential treatments that enhance the quality of life for patients dealing with complex health issues.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · March 5, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · March 5, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · March 4, 2025

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 4, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · March 3, 2025

These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Via Chartmill · March 3, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · March 3, 2025

BioXcel Therapeutics, Inc. (NASDAQBTAI) shares are trading higher Monday following news that the U.S. Food and Drug Administration (FDA) has concluded its inspection of a site involved in the company's Phase 3 TRANQUILITY II trial.
Via Benzinga · March 3, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the most active stocks in today's session.
Via Chartmill · February 28, 2025

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · February 28, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via Chartmill · February 28, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · February 10, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · February 10, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · February 10, 2025

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · February 7, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Via Chartmill · February 6, 2025

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · February 6, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · February 6, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · February 4, 2025

Via Benzinga · January 24, 2025

Via Benzinga · November 22, 2024

BTAI stock results show that BioXcel Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024

BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms.
Via Benzinga · June 25, 2024